__NUXT_JSONP__("/drugs/Conatumumab", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"896731-82-1",chebiId:b,chemicalFormula:b,definition:"A fully human monoclonal agonist antibody directed against the extracellular domain of human TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) receptor 2 (TR-2) with potential antineoplastic activity. Conatumumab mimics the activity of native TRAIL, binding to and activating TR-2, thereby activating caspase cascades and inducing tumor cell apoptosis. TR-2 is expressed by a variety of solid tumors and cancers of hematopoietic origin.",fdaUniiCode:"1P48L61KM0",identifier:"C71015",preferredName:a,semanticType:"Amino Acid, Peptide, or Protein",subclassOf:["C129822","C20401"],synonyms:["AMG 655","Anti-TRAIL Receptor 2 Monoclonal Antibody AMG 655","CONATUMUMAB",a,"Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Receptor Superfamily Member 10b (Death Receptor 5, Trail-R2, CD262 Antigen))","Monoclonal XG1-048 (Arg(Sup 219),Glu(Sup 361),Met(Sup 363))Gamma-1 Heavy Chain (225-215')-Disulphide With Kappa Light Chain (231-231'':234-234'')-Bisdisulphide Dimer"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FConatumumab",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Conatumumab","","2021-10-30T13:43:33.963Z")));